{"entity":{"id":"viper-101","kind":"drug","name":"Senza5 CART5","aka":["VIPER-101"],"tldr":"Senza5 CART5 is an experimental autologous CAR-T cell therapy from Vittoria Biotherapeutics, in phase 1 trials for T-cell non-Hodgkin lymphoma.","summary":"Senza5 CART5 (VIPER-101) is an autologous CAR-T cell therapy (gene-edited, dual-population) from Vittoria Biotherapeutics, with University of Pennsylvania as partner. A gene-edited autologous CD5-directed CAR-T product made of two engineered cell populations, CD5-knockout cells and CD5-knockout CART5 cells. Its furthest stage is phase 1, for T-cell non-Hodgkin lymphoma. ClinicalTrials.gov registers it in 2 studies linked below. Phase 1 NCT06420089 recruiting; long-term follow-up study NCT07683897 not yet recruiting (registry, 3 Nov 2026). Whether it works in people has not been established unless a trial below reports it.","status":"phase-1","asOf":"2026-11-03","links":[{"label":"Vittoria Biotherapeutics: vittoriabio.com","url":"https://vittoriabio.com/pipeline/"},{"label":"Vittoria Biotherapeutics: clinicaltrials.gov","url":"https://clinicaltrials.gov/api/v2/studies/NCT06420089"},{"label":"ClinicalTrials.gov: trials of VIPER-101","url":"https://clinicaltrials.gov/search?intr=VIPER-101"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["non-hodgkin-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["vittoria-biotherapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06420089","nct07683897"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"VIPER-101","modality":"Autologous CAR-T cell therapy (gene-edited, dual-population)","mechanism":"A gene-edited autologous CD5-directed CAR-T product made of two engineered cell populations, CD5-knockout cells and CD5-knockout CART5 cells.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/viper-101/","neighbours":{"cancer":[{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"}],"company":[{"id":"vittoria-biotherapeutics","kind":"company","name":"Vittoria Biotherapeutics","route":"/companies/vittoria-biotherapeutics/"}],"trial":[{"id":"nct07683897","kind":"trial","name":"A Long-Term Follow-Up Trial for Participants Enrolled in CD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) Trials","route":"/trials/nct07683897/"},{"id":"nct06420089","kind":"trial","name":"CD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) for T Cell Non-Hodgkin Lymphoma (NHL)","route":"/trials/nct06420089/"}]}}